Hantavirus — domande con risposte

In generale no. La maggior parte delle specie di hantavirus — incluse Sin Nombre, Puumala, Hantaan e Seoul — si trasmette solo per contatto con roditori infetti o con i loro escrementi, urina e saliva. L'unica eccezione documentata è il virus Andes (ANDV), presente soprattutto in Argentina e Cile. Per il virus Andes è stata registrata una trasmissione interumana limitata, ma solo in casi di contatto stretto e prolungato (per esempio conviventi o operatori sanitari senza protezioni). Il cluster della MV Hondius riguarda il virus Andes, ed è per questo che è in corso un tracciamento dei contatti a livello internazionale nonostante la rarità del contagio interumano.

The MV Hondius 2026 cluster is the first documented hantavirus outbreak linked to cruise ship travel, but the ship environment was not itself the source of transmission. Hantavirus does not spread easily from person to person — the source was an index case who had spent four months in Andes virus-endemic areas of Argentina, Chile, and Uruguay before boarding. Andes virus is the only hantavirus strain with documented (but limited) person-to-person transmission, requiring prolonged close contact. WHO and ECDC assessed the risk to the general public from the MV Hondius cluster as 'low' to 'very low'. The episode demonstrates that travelers returning from Andes-endemic South American regions within 8 weeks of symptoms should disclose that travel history to clinicians immediately.

L'incubazione dell'hantavirus va in genere da 1 a 8 settimane dall'esposizione, con la comparsa dei sintomi più frequente tra le 2 e le 4 settimane dopo il contatto (CDC). Proprio questo lungo periodo di incubazione è uno dei motivi per cui l'OMS prosegue il monitoraggio attivo dei passeggeri e dei contatti della MV Hondius: con lo sbarco di 30 persone a Sant'Elena il 24 aprile 2026 e la presenza dei contatti in 6 paesi, nuovi casi collegati al cluster potrebbero emergere fino a metà giugno 2026.

Ebola is NOT airborne. Human-to-human transmission requires direct contact with the blood or body fluids (saliva, vomit, urine, feces, breast milk, semen) of a symptomatic or deceased infected person, or with surfaces and objects contaminated by those fluids. Traditional burial practices involving contact with the deceased are a well-documented transmission route, as is nosocomial spread in healthcare settings lacking adequate infection control. The virus can also persist in semen for months after recovery, making sexual transmission possible. Animal-to-human spillover is believed to originate from fruit bats (Pteropodidae) and infected non-human primates.

L'hantavirus si trasmette principalmente dai roditori all'uomo attraverso quattro vie. (1) Inalazione di aerosol di urina, escrementi o saliva di roditori infetti — la via più frequente, soprattutto in ambienti chiusi e poco ventilati come baite, garage, capanni e fienili. (2) Contatto diretto con i roditori, i loro escrementi o superfici contaminate, in particolare con pelle lesa o mucose. (3) Morso di un roditore infetto (raro). (4) Consumo di cibo contaminato da escrementi di roditori. Il virus Andes presenta anche rari casi documentati di trasmissione interumana, che richiedono un contatto stretto e prolungato (per esempio conviventi o operatori sanitari senza DPI). L'hantavirus non si trasmette attraverso zanzare, zecche o altri artropodi.

Measles is one of the most contagious infectious diseases known. It spreads through the air via tiny respiratory aerosols and droplets released when an infected person coughs, sneezes, or breathes. The virus can survive in the air and on surfaces for up to 2 hours after an infected person has left a room — meaning you can catch measles without direct contact. The basic reproduction number (R₀) is 12–18: each infectious person can infect 12 to 18 unvaccinated contacts in a susceptible population. An infected person is contagious from about 4 days before their rash appears through 4 days after — roughly 8 days total, often before they know they are sick. Measles has no animal reservoir, which means it can only survive by continuously infecting people. This makes herd immunity — achieved through ≥95% two-dose MMR vaccination — the only sustainable way to stop transmission.

Smallpox spread almost exclusively person-to-person through respiratory droplets and direct contact with skin lesions, and was highly contagious with a basic reproduction number (R0) of 5-7. Mpox is less transmissible: clade IIb (2022 outbreak) spread primarily through close physical and sexual contact, with an estimated R0 of 1.1-2.4 in the MSM community. Mpox also has a zoonotic reservoir (rodents, primates), meaning it can re-enter the human population from animals — unlike smallpox, which had no animal reservoir.

The primary route is contact with the multimammate rat (Mastomys natalensis) — specifically its urine, faeces, or saliva — or by handling and consuming infected rats. Human-to-human transmission occurs through direct contact with blood, urine, faeces, vomit, or other bodily fluids of an infected person. Lassa fever is NOT airborne; casual contact poses minimal risk. Healthcare workers are at risk without adequate PPE. Sexual transmission is documented during convalescence, as the virus persists in semen for up to three months.

L'hantavirus non è 'airborne' nello stesso modo in cui lo sono COVID-19 o morbillo. Si trasmette attraverso aerosol che si generano quando escrementi essiccati di roditore (urina, feci, saliva) vengono mossi e dispersi nell'aria a livello locale — per esempio spazzando una baita infestata o aspirando feci a secco. Questo significa che la quota 'aerea' della trasmissione è a corto raggio e legata a specifiche condizioni ambientali: non è una trasmissione che si protrae nel tempo in stanze condivise, come avviene per i patogeni respiratori. Nemmeno l'eccezione del virus Andes, che richiede contatto stretto e prolungato tra persone, costituisce una trasmissione respiratoria classica. Una ventilazione adeguata (aprire le finestre per almeno 30 minuti prima di entrare in una baita chiusa) riduce efficacemente il rischio.

Lassa fever can spread person-to-person, but is far less contagious than diseases like measles or COVID-19. Transmission requires direct contact with the blood, urine, faeces, vomit, or other bodily fluids of an infected person — casual contact, sharing air, or coughing do not spread the virus. Healthcare workers who treat Lassa patients without adequate PPE are at significant risk. Sexual transmission is documented during convalescence because the virus persists in semen for up to three months. Large household clusters are uncommon; most secondary cases occur in healthcare settings without strict infection control. This is in contrast to Ebola, which has caused much larger nosocomial clusters.

Mpox is not classified as a traditional sexually transmitted infection (STI), but sexual contact is an efficient transmission route. During the 2022 clade IIb global outbreak, the majority of cases in high-income countries involved men who have sex with men (MSM), transmitted through close skin-to-skin contact during sex. The virus spreads via direct contact with lesions, rash, or body fluids — circumstances common during sexual activity. However, mpox also transmits through non-sexual close contact (household, healthcare settings), distinguishing it from classic STIs.

A person with measles is contagious from approximately 4 days before the rash appears through 4 days after rash onset — a total infectious window of about 8 days. This means an infected person is spreading measles before they even know they have it, since the rash does not appear until the disease has been progressing for several days. During the prodromal phase (before the rash), the only symptoms are fever, cough, runny nose, and red eyes — easily mistaken for a common cold or flu. This pre-rash contagiousness is one of the main reasons measles outbreaks are so hard to contain: by the time someone is diagnosed, they may have already exposed many others. People with measles should be isolated from others from 4 days before rash onset through 4 days after rash onset, per CDC guidelines.

Ebola virus disease has a historical case-fatality rate of 25-90% depending on strain, with Bundibugyo ebolavirus — the strain driving the active 2026 outbreak in the Democratic Republic of the Congo and Uganda — historically around 25-40%. Per the WHO Situation Report of 18 May 2026, the outbreak had recorded 528 reported cases (2 lab-confirmed in Uganda, 526 under investigation) and 132 deaths, with 668 contacts identified. No vaccine or monoclonal antibody therapy is currently approved for the Bundibugyo strain, unlike Zaire ebolavirus which has Ervebo and two approved antibody treatments. WHO declared the outbreak a Public Health Emergency of International Concern on 18 May 2026.

La mortalità varia molto in base alla specie virale. Il virus Andes e il virus Sin Nombre, che causano la sindrome polmonare da hantavirus (SPH), hanno un tasso di letalità (CFR) del 30-40%. Le varianti eurasiatiche che causano la febbre emorragica con sindrome renale (HFRS) — Puumala, Hantaan, Seoul — hanno una letalità più bassa: Puumala 0,1-1%, Seoul circa 1-2%, Hantaan 5-15%. Il cluster della MV Hondius riguarda il virus Andes, il ceppo più letale. Degli 8 casi segnalati al 7 maggio 2026, 3 sono deceduti — un tasso di letalità del 37,5% coerente con le statistiche storiche del virus Andes. Non esiste un trattamento antivirale specifico; lo standard di cura è il supporto intensivo (ossigeno, ventilazione, ECMO), tanto più efficace quanto più precoce.

No. Mpox is substantially less dangerous than smallpox. Smallpox had a case fatality rate of approximately 30% and caused disfigurement in survivors. Mpox clade II (responsible for the 2022-2024 global outbreak) has a fatality rate below 1% in high-income settings. Mpox clade I, circulating in Central Africa, carries a higher fatality rate of 1-10%, historically higher in children. Smallpox was eradicated globally in 1980; mpox continues to circulate in animal reservoirs and spreads to humans.

The overall case fatality rate (CFR) is approximately 1%, reflecting the high proportion of mild or asymptomatic cases. In hospitalised patients — who represent the severe end of the spectrum — the CFR rises to 15-25%. Lassa fever accounts for an estimated 5,000 deaths per year across West Africa. Pregnant women in the third trimester face especially high risk: foetal mortality approaches 80%, and maternal mortality is also significantly elevated.

Quasi certamente no, sulla base delle evidenze attuali. Il direttore generale dell'OMS ha dichiarato pubblicamente il 7 maggio 2026 che il cluster della MV Hondius 'non è il prossimo COVID'. Tre motivi strutturali: (1) L'hantavirus non si trasmette in modo efficiente tra esseri umani — il virus Andes, unico ceppo con trasmissione interumana documentata, richiede contatto stretto e prolungato, con R0 effettivo ben inferiore a 1 nelle catene umane. (2) Il serbatoio naturale (specie precise di roditori) è geograficamente vincolato, quindi una diffusione sostenuta richiede i roditori, non solo persone malate. (3) L'elevata letalità (30-40%) rallenta paradossalmente la diffusione, uccidendo o ospedalizzando gli ospiti prima che possano contagiare altri — la classica dinamica del 'troppo letale per diffondersi'. I trader di Polymarket sono d'accordo: il quesito 'Pandemia di hantavirus 2026', dopo il picco del 38% al primo allarme, si è stabilizzato al 9% con 2,2 milioni di dollari scambiati. La vigilanza resta giustificata, vista l'incubazione di 6 settimane, ma una pandemia è altamente improbabile.

The first symptoms of Ebola virus disease appear 2-21 days after exposure (typically 8-10 days) and include abrupt high fever (≥38.6°C/101.5°F), intense headache, severe muscle pain, extreme fatigue, sore throat, and loss of appetite. By days 3-7 a gastrointestinal phase follows, with profuse watery diarrhoea (up to 10 L/day in severe cases), vomiting, abdominal pain, and hiccups. In roughly half of severe cases, a haemorrhagic phase develops around days 5-10 — bleeding from injection sites and mucosal surfaces, and a non-itchy rash on the trunk by day 5-7. A person is not contagious until symptoms begin.

Nelle prime fasi i sintomi di hantavirus e influenza si sovrappongono: entrambi causano febbre, stanchezza, dolori muscolari e mal di testa. I documenti clinici dei CDC indicano quattro elementi di differenziazione. (1) Il dolore muscolare da hantavirus è intenso e concentrato sui grandi gruppi muscolari (cosce, fianchi, parte bassa della schiena); nell'influenza è più diffuso. (2) L'hantavirus raramente provoca sintomi delle alte vie respiratorie nelle fasi iniziali (assenza di naso che cola o mal di gola), che nell'influenza sono comuni. (3) L'hantavirus evolve verso un rapido deterioramento respiratorio dopo 4-10 giorni dall'esordio (fase SPH) — una caratteristica assente nell'influenza. (4) L'hantavirus non ha un andamento stagionale; l'influenza ha il picco in inverno. Le linee guida cliniche dei CDC sottolineano che un'anamnesi di esposizione a roditori o di viaggio in zone endemiche è l'informazione chiave che porta a sospettare hantavirus e a richiedere il test.

Vai al pronto soccorso immediatamente — non aspettare — se si verifica almeno uno di questi tre segnali d'allarme: (1) Dolori muscolari intensi (cosce, fianchi, parte bassa della schiena) con febbre alta superiore a 38 °C, E precedente contatto con roditori o viaggio in aree rurali del Sud America (in particolare Argentina, Cile, Uruguay) nelle ultime 8 settimane. (2) Dispnea progressiva o difficoltà respiratoria che compaiono 4–10 giorni dopo l'inizio della febbre — questo segnala la fase cardiopolmonare potenzialmente letale della Sindrome Polmonare da Hantavirus (SPH), che può evolvere in insufficienza respiratoria nel giro di ore. (3) Qualsiasi sintomo simil-influenzale se sei stato passeggero o membro dell'equipaggio a bordo della MV Hondius (cluster del virus Andes 2026) nelle ultime 6 settimane — informa subito il team d'emergenza dell'itinerario della nave. Le linee guida cliniche dei CDC sottolineano che gli esiti migliorano significativamente con l'ospedalizzazione precoce, la terapia con ossigeno e il monitoraggio in terapia intensiva prima che si sviluppi l'insufficienza respiratoria. L'hantavirus ha un tasso di letalità del 30–40% nella SPH: pensare 'sarà solo l'influenza' è pericoloso se sono presenti i fattori di rischio sopra descritti.

Mpox illness typically lasts 2-4 weeks. A prodromal phase of fever, lymphadenopathy, and fatigue precedes the rash by 1-5 days. The rash phase — lesions progressing macule, papule, vesicle, pustule, scab — lasts 2-3 weeks. A person remains infectious from symptom onset until all scabs have fallen off and new skin has healed beneath them. Milder clade IIb cases from the 2022 outbreak (few lesions limited to the genital area) sometimes resolved in under 2 weeks.

Symptoms begin 6-21 days after exposure. Mild cases present with fever, general weakness, headache, sore throat, and mild gastrointestinal symptoms. Severe cases (about 20% of infections) include high fever, chest pain, vomiting, diarrhoea, facial swelling, and haemorrhagic manifestations (bleeding from gums, nose, or eyes). A key late complication is sensorineural hearing loss, occurring in 25-30% of patients — including those who recover from acute illness — and is often permanent.

Measles begins with 3–4 days of high fever (often above 40°C/104°F), cough, runny nose (coryza), and red, watery eyes (conjunctivitis) — known as the '3 Cs'. A key early sign is Koplik's spots: tiny white or grey-blue dots on the inside of the cheeks, appearing 1–2 days before the rash and pathognomonic (unique) to measles. The hallmark maculopapular rash then starts at the hairline and face, spreading downward to the trunk and limbs over 3 days. Fever peaks when the rash appears, then gradually falls if the illness is uncomplicated. Complications include ear infections (about 1 in 10 children), pneumonia (the leading cause of measles deaths), and, rarely, encephalitis (1–2 per 1,000 cases). A lesser-known long-term risk is immune amnesia: measles can wipe out 11–73% of existing antibody memory for 2–3 years, leaving recovered individuals more susceptible to other infections.

Both diseases begin with fever, headache, back pain, and fatigue, followed by a characteristic rash. The key distinguishing features of mpox are: (1) prominent lymphadenopathy (swollen glands) — absent in smallpox; (2) rash lesions may appear in different stages simultaneously; (3) genital/perianal lesions are common in clade IIb. Smallpox lesions were uniform in stage and deeply embedded in the skin. Mpox lesions evolve through macule, papule, vesicle, pustule, scab, typically over 2-4 weeks. In the 2022 clade IIb outbreak, many cases presented with few lesions limited to the genital area without a classical widespread rash.

L'infezione da hantavirus si manifesta in genere in due fasi (CDC). La fase febbrile iniziale, della durata di 1-7 giorni, include febbre, dolori muscolari intensi (cosce, fianchi, schiena, spalle), stanchezza, mal di testa, vertigini, brividi e talvolta nausea, vomito o dolore addominale. La fase cardiopolmonare tardiva, 4-10 giorni dopo l'esordio nei casi di SPH (Andes, Sin Nombre), comporta tosse, dispnea, edema polmonare e un'insufficienza respiratoria a rapida progressione. Le varianti HFRS (Puumala, Hantaan, Seoul) provocano in più danno renale acuto e manifestazioni emorragiche. Il tratto clinico distintivo dell'hantavirus rispetto a influenza o COVID-19 è il brusco passaggio a un grave deterioramento respiratorio nei casi di SPH.

Yes. China reports the world's highest annual burden of hantavirus disease, with roughly 10,000 to 20,000 cases of hemorrhagic fever with renal syndrome (HFRS) each year — mostly caused by Hantaan virus and Seoul virus carried by Apodemus agrarius (striped field mouse) and Rattus norvegicus (brown rat) respectively. Provinces with the highest incidence are Shaanxi, Heilongjiang, Shandong, and Liaoning. The 2025 epidemiological report from China CDC showed continued decline from 1980s peaks (which exceeded 100,000 cases per year) thanks to rodent control programs and the domestic inactivated bivalent vaccine Hantavax (Hantaan + Seoul, licensed in China since 1994). The MV Hondius 2026 outbreak involves Andes virus — a New World strain unrelated to Chinese-endemic strains — and is therefore epidemiologically separate from China's ongoing HFRS background activity. Travelers to China face very low hantavirus risk in urban areas; rural cabins and grain storage with active rodent infestation are the historical exposure setting.

No. Hantavirus is not an identified health risk for Hajj or Umrah pilgrims. Saudi Arabia's Arabian Peninsula geography does not support endemic hantavirus circulation: no rodent species carrying pathogenic hantavirus strains (such as Andes virus, Sin Nombre virus, or Puumala virus) are established in the region. WHO's Eastern Mediterranean Regional Office (EMRO) does not list hantavirus among zoonotic disease priorities for Saudi Arabia or neighboring Gulf states. The MV Hondius 2026 cluster does not involve any Saudi Arabian, Gulf, or Levantine passengers among confirmed cases or priority contact-tracing lists as of May 2026. For Hajj health priorities, WHO and the Saudi Ministry of Health focus on meningococcal meningitis (ACWY vaccine mandatory for many nationalities), MERS-CoV (Middle East Respiratory Syndrome), respiratory infections, heat illness, and food safety. No hantavirus-specific measures are required or recommended for travel to Saudi Arabia or any other country in the Middle East and North Africa region.

Viaggiare in Sud America è sicuro per la maggior parte degli itinerari, ma i viaggiatori devono conoscere il rischio geograficamente specifico del virus Andes. Le zone a rischio sono le aree rurali — in particolare la Patagonia e la regione dei Four Corners in Argentina (province di Neuquén, Río Negro, Chubut, Santa Cruz), il Cile meridionale (Regioni X–XIV) e parti dell'Uruguay — non le grandi città come Buenos Aires, Santiago o Montevideo. L'OMS non ha emesso alcuna raccomandazione di non viaggiare in Sud America per l'hantavirus. Il cluster della MV Hondius nel 2026 è partito da un singolo caso indice che aveva trascorso quattro mesi in queste aree rurali endemiche. Precauzioni raccomandate: evitare di dormire in rifugi rurali, fienili o edifici infestati da roditori; in campeggio, usare piattaforme sopraelevate lontane dall'habitat dei topi di campo; non spazzare mai i residui di roditori in spazi chiusi — inumidirli prima con soluzione di candeggina 1:10. Chi sviluppa febbre, dolori muscolari intensi e difficoltà respiratorie entro 8 settimane dal rientro da aree rurali endemiche in Argentina o Cile deve comunicare immediatamente questa storia di viaggio ai medici d'emergenza.

Hantavirus risk follows rodent population cycles, which vary by region and species. United States (Sin Nombre virus): cases peak in late spring and early summer (May–July) in the US Southwest, correlating with the deer mouse (Peromyscus maniculatus) breeding season that drives rodents into human structures — cabins, barns, and outbuildings closed over winter. The CDC notes that 'spring cleaning' of rural cabins without proper precautions (sweeping dry droppings without a mask) is a recurring documented exposure scenario. Scandinavia and Northern Europe (Puumala virus): cases spike in autumn and winter when bank voles (Myodes glareolus) move into homes and farm buildings. Outbreak years correlate with vole population boom cycles every 3–4 years. South America (Andes virus): year-round transmission with no sharply defined peak; cases rise slightly in autumn and winter in Argentina and Chile when cooler temperatures push rodents indoors. The MV Hondius index case was exposed between November 2025 and April 2026 — an autumn-to-early-autumn window in the Southern Hemisphere. Traveler advice: high-risk activities in endemic regions (wilderness camping, cleaning rural structures) carry elevated risk during local rodent breeding seasons. Check CDC country-specific travel advisories before visiting endemic areas.

Le specie di hantavirus sono distribuite a livello globale, con specializzazione regionale. Americhe: virus Sin Nombre (regione dei Four Corners negli Stati Uniti — NM, AZ, CO, UT — oltre a CA, OR, WA), virus Andes (Argentina, Cile, Uruguay), virus Bayou e Black Creek Canal (stati del Golfo USA), virus Choclo (Panama). Europa: virus Puumala (Scandinavia, Baltico, Russia, Germania, Francia, Belgio, presenza limitata nell'Italia settentrionale), Dobrava-Belgrado (Balcani). Asia: virus Hantaan (Cina, Corea), virus Seoul (diffusione globale tramite i ratti delle chiaviche), virus Amur (Russia orientale). Africa: virus Sangassou (Guinea — patologia umana ancora poco conosciuta). L'epidemia della MV Hondius riguarda il virus Andes, di provenienza sudamericana. La nave si trova attualmente al largo di Capo Verde (Africa occidentale, dove non vi è hantavirus endemico) ed è diretta alle Isole Canarie, in Spagna.

There is no documented endemic hantavirus circulation in the Arabian Peninsula (Saudi Arabia, United Arab Emirates, Qatar, Kuwait, Bahrain, Oman, Yemen) or in the Levant (Jordan, Lebanon, Syria, Iraq, Palestine, Israel). Limited serological surveys in Egypt and Turkey have detected hantavirus antibodies in commensal rodents (likely Seoul virus from Rattus norvegicus), but no clinically significant human cases linked to those reservoirs have been reported. The WHO Eastern Mediterranean Regional Office (EMRO) does not list hantavirus among priority emerging zoonoses for the region. The MV Hondius 2026 outbreak does not currently involve any Middle Eastern country in confirmed-case or contact-tracing lists. Risk to residents and travelers within the region remains very low, including for pilgrims attending Hajj or Umrah in Saudi Arabia, where the primary health concerns remain meningococcal disease, MERS-CoV, respiratory infections, and heat illness.

In Italia non sono documentati casi autoctoni di malattia da hantavirus. Il virus Puumala (PUUV) — una specie meno aggressiva, responsabile di HFRS — ha una presenza limitata in alcune aree alpine settentrionali (Trentino-Alto Adige, Friuli-Venezia Giulia), ma non risultano casi umani recenti. L'ECDC valuta il rischio per la popolazione europea generale derivante dall'epidemia della MV Hondius come 'molto basso'. Il Ministero della Salute italiano ha comunque rafforzato la sorveglianza per i viaggiatori di rientro dal Sud America entro la finestra di esposizione rilevante.

Yes — measles is back in the United States and in several other countries in 2026. The US is experiencing its largest measles resurgence in decades: over 2,104 confirmed cases were reported to the CDC by mid-2026, surpassing every annual total since before the disease was declared eliminated in 2000. The outbreak is driven entirely by communities with low two-dose MMR vaccination coverage, not by a change in the virus itself. The measles virus (Measles morbillivirus) is genetically unchanged and the MMR vaccine remains highly effective (97% with two doses). States most affected include Texas, Montana, and others where pockets of unvaccinated individuals allowed the virus to sustain chains of transmission. Globally, WHO reports active outbreaks in Romania, Italy, the Democratic Republic of Congo, and several countries in sub-Saharan Africa and Southeast Asia in 2025–2026. Measles is not 'back' as an endemic pathogen in the USA — elimination status is maintained as long as no continuous year-round chain of domestic transmission is established — but the current outbreak is a serious public-health warning about the consequences of falling vaccination rates.

Nigeria has the highest reported burden, with thousands of cases annually tracked by the Nigeria Centre for Disease Control (NCDC). Sierra Leone, Liberia, and Guinea are also highly endemic. Sporadic cases have occurred in Mali, Ivory Coast, and Benin. International importation has been recorded in Europe and North America among returning travellers. The WHO regularly issues Disease Outbreak News alerts for Nigeria, with peak transmission typically between January and April.

Yes. The United States is experiencing a significant measles resurgence in 2025–2026, with case counts reaching levels not seen since 2019. Outbreaks have been concentrated in communities with low MMR vaccination rates — particularly among unvaccinated children and adults in states including Texas, Montana, and others. Measles was declared eliminated from the USA in 2000, meaning there is no longer sustained year-round transmission; however, outbreaks still occur when unvaccinated travelers import the virus and it spreads through under-immunized pockets of the population. The CDC monitors all cases and recommends two-dose MMR vaccination as the primary prevention measure. International travel to countries with active measles transmission increases exposure risk for unvaccinated individuals. Parents should confirm their children have received two MMR doses on schedule; adults who are unsure of their vaccination history should consult a physician.

The MV Hondius hantavirus cluster (Andes virus, 2026) spans multiple countries across four continents. Countries with confirmed or suspected patients receiving treatment: Netherlands (two confirmed deaths; ship is Dutch-flagged), Germany (patient transferred by medical evacuation), Switzerland (patient hospitalized), South Africa (patient transferred by medical evacuation), and Saint Helena (30 passengers disembarked 24 April 2026). Countries with active contact-tracing operations for passengers or crew who traveled onward: United States (17 American nationals were aboard), United Kingdom, France, Spain (final port call scheduled Las Palmas, Canary Islands, approximately 11 May 2026), Canada, Singapore. Countries involved in the index case's pre-embarkation travel (Andes virus exposure corridor): Argentina (Ushuaia departure port; index case traveled through southern Argentina for four months), Chile, Uruguay. WHO Disease Outbreak News DON599 covers 23 nationalities aboard. ECDC rates the risk to EU/EEA general public as 'very low'.

Hantavirus is diagnosed using a combination of laboratory tests and clinical criteria. The gold standard for Hantavirus Pulmonary Syndrome (HPS) is serology: IgM and IgG ELISA antibody tests that become positive within days of symptom onset. RT-PCR (reverse-transcription polymerase chain reaction) can detect viral RNA in blood during the early febrile phase before antibodies develop, and was used to confirm Andes virus in the MV Hondius cluster cases. Supportive CBC findings include thrombocytopenia (platelets often below 150,000/µL), immunoblasts (activated lymphocytes), hemoconcentration (rising hematocrit), and left-shifted neutrophilia. Chest X-ray and CT show bilateral interstitial infiltrates as HPS progresses to pulmonary edema. Diagnosis typically combines a compatible clinical picture, recent rodent exposure or travel to an endemic area, and confirmatory serology or PCR. Standard influenza or COVID-19 tests will NOT detect hantavirus — physicians must order specific hantavirus serology panels, available through most state and national reference laboratories in the US, EU, Argentina, and Chile.

The MV Hondius 2026 Andes hantavirus outbreak unfolded over six months across four continents. November 2025–April 2026: Patient Zero travels overland for four months through Argentina, Chile, and Uruguay — the endemic zone for Andes virus — before boarding. April 1, 2026: MV Hondius departs Ushuaia, Argentina with 197 passengers and crew from 23 nationalities. April 6: First passenger develops symptoms; hantavirus not yet suspected. April 11: First fatality — a Dutch passenger dies five days after symptom onset; hantavirus identified retroactively from preserved samples. April 24: 30 passengers disembark at Saint Helena (remote South Atlantic island), triggering a global contact tracing operation across six additional countries. May 4: WHO opens Disease Outbreak News DON599 — the first international alert — confirming a multi-country hantavirus cluster. May 5: Polymarket's 'Hantavirus pandemic 2026' market peaks at 38% probability, with $1.3 million in trading volume. May 7: WHO Director-General states the outbreak is 'not the next COVID'; 5 confirmed cases, 2 deaths confirmed; 2,500 diagnostic kits dispatched to five countries. May 11: MV Hondius arrives Las Palmas de Gran Canaria (Canary Islands, Spain) for final disembarkation of remaining 146 passengers. June 2026: Active contact tracing continues in multiple countries within the 8-week incubation window; total confirmed deaths: 3.

Il cluster della MV Hondius è il focolaio di hantavirus attivo nel 2026. I dati in tempo reale — casi confermati, casi sospetti, decessi, paesi coinvolti e persone in tracciamento dei contatti — sono visualizzati nella barra KPI della homepage e si aggiornano ogni ora da D1. I pazienti sono ricoverati in Paesi Bassi, Germania, Svizzera, Sudafrica e Sant'Elena; il tracciamento dei contatti è attivo in Stati Uniti, Singapore, Canada, Francia, Regno Unito e Spagna. OMS, CDC, ECDC, PAHO e Africa CDC hanno tutti emesso aggiornamenti situazionali. I mercati di previsione su Polymarket tracciano la probabilità che l'OMS dichiari una pandemia nel 2026 — vedi la sezione Mercati per le probabilità in diretta. Tutti i dati si aggiornano ogni ora da oltre 50 fonti.

Al 7 maggio 2026 il cluster MV Hondius conta 8 casi segnalati (5 confermati in laboratorio e 3 sospetti in attesa di conferma) e 3 decessi. I casi interessano 5 paesi dove i pazienti sono ospedalizzati: Paesi Bassi, Germania, Svizzera, Sudafrica e Sant'Elena. Il tracciamento dei contatti è attivo in almeno altri 6 paesi: Stati Uniti, Singapore, Canada, Francia, Regno Unito e Spagna. Al di fuori del cluster Hondius, ogni anno si registrano casi sporadici di hantavirus nelle aree endemiche: in genere 20-40 all'anno negli Stati Uniti (Sin Nombre), 100-200 in Argentina (Andes) e diverse migliaia di casi di HFRS in tutta l'Eurasia (Puumala, Hantaan, Seoul). L'attuale epidemia non è insolita per il numero assoluto di casi, ma per la sua distribuzione su più paesi tramite una crociera.

No. Mpox is not eradicated. Smallpox is the only human disease ever declared eradicated (WHO, 1980), achieved through a global vaccination campaign. Mpox continues to circulate in animal reservoirs (primarily rodents in Central and West Africa) and causes recurrent human outbreaks. The 2022-2024 global mpox outbreak (clade IIb) led the WHO to declare a Public Health Emergency of International Concern (PHEIC) twice: in 2022 and again in August 2024 when clade I expanded in the DRC and neighbouring countries. Eradication of mpox is not currently feasible given its animal reservoir.

Il virus Andes (ANDV) è una specie di hantavirus endemica nel Sud America meridionale, in particolare in Argentina, Cile e in parti di Uruguay e Bolivia. Prende il nome dalla cordigliera delle Ande, dove è ampiamente distribuito il suo serbatoio naturale principale, il topo coda lunga pigmeo (Oligoryzomys longicaudatus). L'ANDV causa la sindrome polmonare da hantavirus (SPH) con una letalità del 30-40% ed è unico fra gli hantavirus nella capacità di trasmissione interumana limitata, documentata in cluster già a partire dall'epidemia di El Bolsón, in Argentina, nel 1996. Il cluster della MV Hondius riguarda il virus Andes: il caso indice ha viaggiato a lungo tra Argentina, Cile e Uruguay tra novembre 2025 e aprile 2026.

Ebola virus disease (EVD) is a severe, often fatal illness caused by viruses of the Ebolavirus genus (family Filoviridae). Six species are known — Zaire, Sudan, Bundibugyo, Taï Forest, Reston, and Bombali ebolavirus — with case-fatality rates historically ranging 25-90% depending on strain and access to care. The natural reservoir is believed to be fruit bats (Pteropodidae); spillover to humans occurs via contact with infected wildlife, then spreads human-to-human through direct contact with blood or body fluids. The active 2026 outbreak in the Democratic Republic of the Congo and Uganda, declared a WHO Public Health Emergency of International Concern on 18 May 2026, is caused by Bundibugyo ebolavirus, for which no vaccine or monoclonal antibody therapy is currently approved.

L'hantavirus è una famiglia di virus a RNA (famiglia Hantaviridae) trasmessi principalmente dai roditori all'essere umano. A seconda della specie virale, causa due sindromi distinte: la sindrome polmonare da hantavirus (SPH/HPS), caratterizzata da grave insufficienza respiratoria e mortalità del 30–40% nelle Americhe (virus Andes e Sin Nombre), e la febbre emorragica con sindrome renale (HFRS), che colpisce i reni in Eurasia (virus Hantaan, Puumala, Seoul) con mortalità dell'1–15%. Non esiste un antivirale specifico né un vaccino approvato a livello internazionale. Il contagio avviene principalmente per inalazione di aerosol da escrementi di roditori infetti (urina, feci, saliva). Nel 2026, il cluster attivo principale riguarda il virus Andes, collegato alla nave da crociera MV Hondius.

Lassa fever is an acute viral haemorrhagic illness caused by Lassa mammarenavirus (Arenaviridae family). It is endemic in West Africa — primarily Nigeria, Sierra Leone, Liberia, and Guinea — and was first identified in 1969 in Lassa, Nigeria. The disease is a zoonosis: its primary reservoir is the multimammate rat (Mastomys natalensis). Approximately 80% of infections are mild or asymptomatic; the remaining 20% can progress to severe disease involving haemorrhagic manifestations and multi-organ failure.

Al 7 maggio 2026 la MV Hondius si trova nelle acque territoriali di Capo Verde, con l'OMS e un esperto medico imbarcato che supervisionano la valutazione a bordo. La nave è attesa a Las Palmas, nelle Isole Canarie (Spagna), intorno all'11 maggio 2026, dove avverrà lo sbarco finale e lo screening medico dei 146 passeggeri ancora a bordo, provenienti da 23 paesi. Tra i precedenti sbarchi ci sono i 30 passeggeri scesi a Sant'Elena il 24 aprile e singole evacuazioni mediche verso Sudafrica, Paesi Bassi, Germania e Svizzera. La nave è partita da Ushuaia, in Argentina, il 1° aprile 2026.

Isolation requirements differ by hantavirus species. For most variants (Sin Nombre, Puumala, Hantaan, Seoul): standard contact precautions are sufficient because there is no documented human-to-human transmission. Healthcare workers should use standard PPE (gloves, surgical mask, eye protection) during procedures that generate aerosols from bodily fluids. For Andes virus — the strain in the MV Hondius 2026 cluster — WHO and ECDC recommend upgraded droplet-plus-contact precautions given the documented, albeit rare, human-to-human transmission risk. This means N95 or equivalent respirator, gown, gloves, and eye shield for direct patient care. The CDC advises airborne precautions (negative-pressure room + N95) when performing high-aerosol procedures such as intubation or bronchoscopy on suspected HPS patients. In the MV Hondius outbreak, WHO distributed 2,500 diagnostic kits and issued specific healthcare-worker guidance emphasizing that Andes virus requires a heightened precautionary approach. Household contacts of Andes virus patients should self-monitor for symptoms for 8 weeks from last exposure; they do not require medical isolation unless symptomatic.

Le indicazioni di prevenzione dei CDC puntano a ridurre al minimo l'esposizione ai roditori. Le raccomandazioni standard sono: (1) Sigillare le aperture superiori a circa 6 mm in abitazioni, capanni e baite per impedire l'ingresso dei roditori. (2) Catturare i roditori con trappole a scatto nelle zone problematiche; non usare solo veleno (le carcasse vanno comunque rimosse in sicurezza). (3) Prima di entrare in edifici rimasti chiusi a lungo (baite, garage, depositi), aprire porte e finestre per almeno 30 minuti per arieggiare. (4) Inumidire polvere ed escrementi con una soluzione di candeggina (1:10) prima di pulire; non spazzare né aspirare a secco i residui di roditori, perché si aerosolizzano particelle virali. (5) Indossare guanti in lattice o gomma e una mascherina N95 quando si maneggia materiale potenzialmente contaminato. (6) Conservare gli alimenti in contenitori a prova di roditore. Chi viaggia in regioni endemiche dovrebbe evitare di dormire in baite o tende infestate da roditori.

Prevention focuses on reducing contact with the multimammate rat (Mastomys natalensis), the primary animal reservoir. Key measures recommended by the WHO and CDC include: (1) Store food in rodent-proof containers and dispose of garbage away from the home. (2) Keep homes clean and seal entry points to discourage rats. (3) Avoid contact with rodents, their nests, urine, or faeces. (4) Healthcare workers must use appropriate personal protective equipment (PPE) — gloves, gowns, masks — when caring for suspected or confirmed Lassa fever patients, and follow strict infection control protocols. (5) Community education in endemic areas (Nigeria, Sierra Leone, Liberia, Guinea) on the risks of handling or consuming rats. There is currently no approved vaccine for Lassa fever, though multiple candidates are in clinical development under CEPI funding.

The MMR (measles-mumps-rubella) vaccine is highly effective. A single dose provides approximately 93% protection against measles; two doses provide approximately 97% protection. The two-dose schedule — first at 12–15 months, second at 4–6 years — is the global standard recommended by WHO and CDC and is why measles was declared eliminated from the USA in 2000. Protection from two doses is generally lifelong for the vast majority of vaccinated people. Adults born before 1957 are presumed immune from prior natural infection. Adults born in 1957 or later who haven't had measles or received two vaccine doses should get vaccinated. The 2025–2026 USA resurgence is driven entirely by communities with low two-dose MMR coverage — not by the vaccine failing, but by vaccination gaps allowing the virus to find susceptible hosts.

WHO and ECDC issued specific guidance for the approximately 197 passengers and crew aboard MV Hondius following the Andes hantavirus cluster. Recommended actions: (1) Self-monitor daily for fever (>38°C / 100.4°F), severe muscle aches in the thighs, hips, or back, fatigue, or any breathing difficulty for 8 weeks from last potential exposure aboard the ship. (2) If symptoms develop, call emergency services immediately and inform them of your travel on MV Hondius — do not self-drive to an emergency room. Provide the ship's name, dates aboard, and cabin number to the receiving healthcare team. (3) Passengers who disembarked at Saint Helena on 24 April 2026 should have already been contacted by local health authorities; if not, contact your national health authority directly. (4) Normal daily activities including work may continue while asymptomatic — Andes virus is NOT spread through casual contact, shared office air, or public transport. (5) Defer blood donation until 8 weeks after disembarkation. WHO distributed diagnostic kits to all countries known to host former passengers or crew, covering 23 nationalities. Your national traveler health hotline can provide country-specific guidance.

Yes. Smallpox vaccines provide cross-protection against mpox because both viruses are orthopoxviruses. The JYNNEOS vaccine (MVA-BN, Imvamune/Imvanex) is specifically approved for both mpox and smallpox prevention. ACAM2000 (the replication-competent vaccinia vaccine) is also protective but carries more side-effect risks. Pre-1980 smallpox vaccination campaigns conferred approximately 85% protection against mpox; that immunity has waned in the global population since routine vaccination stopped. JYNNEOS is now recommended as a 2-dose series for at-risk individuals in many countries.

Survivors of Hantavirus Pulmonary Syndrome (HPS) can make full recoveries, but the critical window is narrow. Once the cardiopulmonary phase begins — typically 4–10 days after symptom onset — patients may deteriorate rapidly from mild dyspnea to full respiratory failure within hours. Early ICU admission with supplemental oxygen, mechanical ventilation, and in severe cases ECMO (extracorporeal membrane oxygenation, heart-lung bypass) is the standard of care and significantly improves survival odds. Most survivors who receive adequate ICU support are discharged within 2–6 weeks. Long-term sequelae: some HPS survivors experience reduced pulmonary function for several months but most regain normal lung capacity within a year. There is no known chronic carrier state for hantavirus — the virus does not persist indefinitely after recovery. Hemorrhagic Fever with Renal Syndrome (HFRS) variants (Puumala, Hantaan) have a better prognosis overall (case fatality 0.1–15%) and renal function typically recovers, though dialysis may be needed acutely. The three deaths in the MV Hondius 2026 cluster occurred before ECMO could be initiated, underscoring that rapid recognition and early ICU transfer are the main modifiable survival factors.

A maggio 2026 nessun vaccino contro l'hantavirus è approvato da OMS, FDA o EMA. Corea del Sud e Cina utilizzano a livello nazionale vaccini inattivati contro l'hantavirus (per esempio Hantavax) per i ceppi HFRS (Hantaan, Seoul), ma non sono approvati a livello internazionale e non proteggono dai ceppi del Nuovo Mondo che causano SPH (Andes, Sin Nombre). Diversi candidati vaccinali contro i virus Andes e Sin Nombre sono in fase iniziale di ricerca o di sperimentazione di fase 1, ma nessuno è atteso all'approvazione prima del 2028. Il mercato Polymarket 'Vaccino contro l'hantavirus approvato nel 2026?' è attualmente scambiato al 2% di probabilità.

For Zaire ebolavirus, yes: Ervebo (rVSV-ZEBOV-GP, Merck) has been FDA/EMA-approved since 2019 and is used in ring vaccination during outbreak response, and two monoclonal antibody therapies — Ebanga (mAb114) and Inmazeb (REGN-EB3) — are FDA-approved and reduce mortality when given early. Sudan ebolavirus vaccine candidates are in advanced trials but not yet WHO-prequalified. Critically, the active 2026 outbreak in the DRC and Uganda is caused by Bundibugyo ebolavirus, for which no vaccine or monoclonal antibody therapy is currently approved — treatment there relies on supportive intensive care (fluids, electrolyte balance, oxygen, blood pressure support).

Ribavirin, an antiviral drug, is effective when given early — ideally within 6 days of fever onset. Early supportive care (IV fluids, electrolyte correction, treating secondary infections) also significantly improves outcomes. Convalescent plasma has been explored but its efficacy is not firmly established. There is currently no WHO-approved vaccine for Lassa fever, though multiple vaccine candidates are in clinical development.

There is no approved specific antiviral drug for measles. Treatment is supportive — meaning it aims to reduce symptoms and prevent complications rather than directly kill the virus. Key elements include: adequate hydration, fever management with acetaminophen or ibuprofen (never aspirin in children), and vitamin A supplementation — WHO recommends two high-dose vitamin A doses for all children with measles, as it has been shown to significantly reduce measles mortality and the severity of complications including blindness and pneumonia. Secondary bacterial infections (the most common cause of measles-related deaths in both children and adults) are treated with appropriate antibiotics. Severe pneumonia and measles encephalitis require hospitalization and may need intensive care. The best 'treatment' remains prevention: two doses of MMR vaccine before exposure provide lifelong protection in ~97% of recipients.

Tecovirimat (TPOXX/ST-246) is an antiviral approved by the FDA and EMA specifically for the treatment of orthopoxvirus infections including mpox. Brincidofovir and cidofovir are alternative antivirals used in severe cases. For most people with clade II mpox, illness is self-limiting and resolves within 2-4 weeks with supportive care (pain management, wound care, hydration). Severe cases — clade I infection, immunocompromised patients, children, or extensive skin involvement — require antiviral treatment and may need hospitalisation.

I due virus differiscono praticamente su tutti i parametri epidemiologici rilevanti. Trasmissione: il COVID-19 (SARS-CoV-2) si diffonde in modo efficiente per via aerea, tramite droplet e aerosol respiratori, tra esseri umani; l'hantavirus è principalmente zoonotico (roditori-uomo), con il virus Andes come unica specie che ha mostrato rari casi di trasmissione interumana per contatto stretto e prolungato. R0 (numero di riproduzione di base): COVID-19 originario 2-3, varianti attuali fino a 8-15; virus Andes R0 nella trasmissione interumana <1, il che rende improbabili catene di contagio sostenute. Mortalità: COVID-19 con letalità complessiva dello 0,5-2%; hantavirus Andes 30-40%. Potenziale pandemico: il COVID-19 ha causato milioni di morti nel mondo; l'hantavirus non ha mai provocato una pandemia e l'OMS valuta il rischio attuale come basso. Il cluster della MV Hondius, con 8 casi al 7 maggio 2026, è un evento zoonotico contenuto, non l'inizio di una pandemia.

Hantavirus vs Ebola — mortalità 30-40% vs 25-90%, serbatoio roditori vs pipistrelli, nessun vaccino vs Ervebo. 7 differenze chiave e dati live 2026. (1) Serbatoio: hantavirus nei roditori (topi cervo, arvicole); Ebola in pipistrelli della frutta e primati non umani. (2) Trasmissione interumana: hantavirus rara (solo ceppo Andes, contatto stretto prolungato); Ebola sì, in modo efficiente via fluidi corporei, fino a focolai di migliaia di casi. (3) Mortalità: sindrome polmonare da hantavirus (HPS) 30-40% (virus Andes); Ebola 25-90% a seconda del ceppo — Ebola Zaire storicamente 50-90%. (4) Vaccino: hantavirus nessuno approvato a livello internazionale; Ebola ha Ervebo (rVSV-ZEBOV) approvato da FDA ed EMA dal 2019 per il ceppo Zaire, più candidati avanzati per il ceppo Sudan. (5) Terapia: entrambi richiedono terapia intensiva di supporto; Ebola ha inoltre due anticorpi monoclonali approvati FDA — Inmazeb (REGN-EB3) ed Ebanga (mAb114), che riducono drasticamente la mortalità se somministrati precocemente. (6) Focolai principali: hantavirus Argentina 1996, USA 1993 (Four Corners) e l'attuale cluster MV Hondius 2026. Ebola Africa occidentale 2014-2016 (28.600 casi / 11.300 decessi), RDC 2018-2020 (3.470 casi / 2.287 decessi), più focolai ricorrenti in Uganda. (7) Potenziale pandemico: entrambi storicamente regionali; nessuno ha mai raggiunto livello pandemico globale. Traccia entrambi live: cluster MV Hondius su outbreakwatch.net e Ebola Situation Watch 2026 su outbreakwatch.net/ebola.

Both are African viral haemorrhagic fevers, but they differ significantly. Lassa is caused by an arenavirus, Ebola by a filovirus. Lassa is endemic and causes tens of thousands of cases annually; Ebola causes sporadic large outbreaks. Lassa's overall CFR (~1%) is much lower than Ebola's (25-90%), though hospitalised Lassa patients face higher mortality (~15-25%). Lassa does not spread person-to-person as easily as Ebola. Both require similar PPE for healthcare workers.

Mpox and smallpox are both caused by orthopoxviruses, but they are distinct diseases. Smallpox (Variola virus) was eradicated in 1980 and no longer occurs naturally. Mpox (Monkeypox virus) is an ongoing zoonotic disease, with outbreaks in 2022-2024 (clade IIb, global) and 2024-2025 (clade I, primarily Democratic Republic of Congo). Key clinical difference: mpox causes prominent lymphadenopathy (swollen lymph nodes), which does NOT occur in smallpox. Mpox is significantly less severe: clade II fatality rate is under 1%, while smallpox killed approximately 30% of those infected.

I mercati di previsione sono ragionevolmente calibrati per eventi con scambi consistenti e ampie informazioni pubbliche, ma presentano limiti noti quando si parla di nuove epidemie. Punti di forza: aggregano prospettive diverse e si aggiornano rapidamente con i nuovi dati. Limiti nel caso delle epidemie: (1) liquidità ridotta nei mercati nelle prime fasi — pochi trader possono spostare i prezzi in modo significativo. (2) Rischio di risoluzione — può essere controverso decidere che cosa costituisca una 'dichiarazione ufficiale di pandemia'. (3) Asimmetria informativa — le autorità sanitarie dispongono di dati privati non accessibili ai trader. (4) Riflessività — quando i mercati diventano notizia, possono influenzare l'evento che cercano di prevedere. Il mercato Polymarket 'Pandemia di hantavirus 2026' supera attualmente i 3,5 milioni di dollari di volume: una liquidità sufficiente a resistere alla manipolazione di singoli trader, ma comunque volatile e sensibile alle dichiarazioni dell'OMS.

Un mercato di previsione è una piattaforma online in cui i partecipanti comprano e vendono quote il cui valore dipende dall'esito di un evento futuro. Per gli eventi sì/no, una quota SÌ paga 1 $ se l'evento si verifica e 0 $ in caso contrario; il prezzo corrente, compreso tra 0 e 1, rappresenta la stima aggregata della probabilità che il mercato attribuisce all'evento. Per esempio, se le quote SÌ di 'Pandemia di hantavirus nel 2026?' sono scambiate a 0,09 $, la probabilità stimata dalla folla è del 9%. I principali mercati di previsione sono Polymarket (basato su criptovalute, globale) e Kalshi (borsa di derivati regolamentata negli Stati Uniti). Sono spesso usati dai ricercatori come segnale predittivo per eventi che vanno dalle elezioni alle epidemie, perché aggregare le scommesse di molti trader può produrre probabilità ben calibrate. OutbreakWatch mostra i dati di Polymarket e Kalshi; non facilita gli scambi.

Il mercato 'Pandemia di hantavirus nel 2026?' su Polymarket è stato uno dei mercati sanitari più volatili dell'anno. Aperto il 4 maggio 2026 al 3,5%, è salito al 38% il 5 maggio in seguito alle prime notizie di trasmissione interumana e decessi, per poi tornare al 9% il 7 maggio dopo che il direttore generale dell'OMS ha pubblicamente descritto il cluster come 'non il prossimo COVID'. Il volume totale di scambi ha superato i 2,2 milioni di dollari. Il movimento riflette una valutazione collettiva in tempo reale di tre segnali: (1) il framing del rischio da parte dell'OMS, (2) i nuovi casi al di fuori del cluster iniziale della nave e (3) il periodo di incubazione di 6 settimane, che lascia aperta la possibilità di nuovi casi fino a metà giugno 2026. Il mercato si risolve il 31 dicembre 2026: i partecipanti stanno prezzando l'intero rischio sui restanti 8 mesi.